AmerisourceBergen Corp. (NYSE:ABC) is among the largest international pharmaceutical sourcing and distribution companies corporations that focuses on the distribution of branded and generic prescription drugs and over-the-counter healthcare merchandise. It’s considered one of the “large three” – main drug distributors within the U.S. – with McKesson Corp. (MCK) and Cardinal Well being (CAH). The corporate additionally operates worldwide companies by means of its segments AmerisourceBergen Alliance Healthcare and International Commercialization Companies, however associated revenues signify solely about 5% of whole 2021 revenues ($214 billion). ABC additionally distributes animal health-related merchandise, however this phase can be comparatively small, with $4.7 billion in revenues in 2021 (2.2%). The corporate additionally presents advertising and marketing, merchandising, and administrative help companies to smaller pharmacies and distributors.
ABC operates a – at first look – commoditized intermediary’s enterprise. Nevertheless, the transportation of highly-valued prescription drugs is closely regulated and thus ABC, MCK and CAH might be seen as working in a consolidated oligopoly. With TTM revenues of $214 billion, ABC is a bit smaller than MCK ($264 billion) however bigger than CAH ($177 billion). The businesses’ predominant worth proposition is simplification of logistics. The “large three” can negotiate very successfully due to their bulk method and their well-developed distribution networks. Nevertheless, which means that the pharmaceutical distributors have to take care of important working capital accounts which makes cashflow productiveness a problem.
On this article, I’ll focus on the corporate’s fundamentals, progress prospects and dangers. I’ll element, why I take into account ABC the best-in-class prescription drugs distributor and description its potential as a dividend progress inventory on the present share worth of $140. The article discusses monetary information of not less than the final decade and the place relevant, I do take steerage or the latest quarterly outcomes into consideration.
Progress And Profitability
As a sourcing and distribution companies firm for prescription drugs, ABC is comparatively uncorrelated with enterprise cycles and sometimes grows revenues at a fee, in-line with pharmaceutical corporations. ABC’s income compounded annual progress fee (CAGR) since 2010 is an astonishing 9.6%, and the expansion fee didn’t gradual in more moderen years. Fairly the opposite, considering steerage for fiscal 2022, additionally the three-year CAGR is nearly 10%. Opponents McKesson and Cardinal Well being have seen annual income progress of about 9% and 5%, respectively, over the previous decade.
The steady income trajectory is an indicator that the sector typically – and AmerisourceBergen specifically – has pricing energy as a result of robust place as a extremely regulated middleman. Nevertheless, the downstream positioning of the businesses and the extent of revenues already recommend that revenue margins should be pretty skinny. ABC’s 12-year common gross and adjusted working margins are 2.9% and 1.0%, respectively. Opponents MCK and CAH exhibit very comparable working margins.
ABC’s gross margin remained very steady since not less than 2010, however adjusted working margin declined from round 1.5% to 1.0%, largely as a result of worker severance funds. Be aware that I adjusted working earnings for the litigation-related expense in 2020. In fiscal 2020 (ending September 30, 2020), the corporate reported a GAAP working lack of $5.14 billion as a result of severance and litigation prices of $6.81 billion. This was a (at first) largely non-cashflow-relevant cost as a result of the settlement shall be paid over the approaching years. The litigation-related prices are associated to the corporate’s opioid lawsuits, and the three distributors proposed to pay a mixed $18 billion settlement. Lately, the variety of folks dying from prescribed, opioid-based painkillers has gone up dramatically. Numerous lawsuits have focused pharmaceutical corporations, but additionally medical doctors and distributors. It would seem obscure why the get together that solely transports the opioid painkillers is being sued, however it may be argued that ABC (in addition to MCK and CAH) ought to have famous the upper prescription volumes in sure areas and acted accordingly. I’m not within the place to guage whether or not the businesses didn’t discover the issue or outright selected to disregard the issue for the sake of elevated revenues.
The corporate’s free cashflow (FCF) is rather more unstable than its top-line, partly as a result of skinny margin construction. Adjusting FCF for working capital actions (which might be important for ABC, see above), stock-based compensations (which I assume to lead to shareholder dilution or require buybacks to offset dilution) and recurring impairments, yields normalized free cashflow (nFCF). Be aware that the $6.2 billion cost as a result of aforementioned settlements was not cashflow-relevant in 2020, however the legal responsibility was decreased by $237 million in fiscal 2021, thereby decreasing cashflow from operations. After all, I didn’t add this cost again when calculating nFCF, because the legal responsibility from the litigation will nonetheless be cashflow related for a number of years.
Nonetheless, ABC continues to generate robust nFCF, and taking steerage of $2.25 billion for fiscal 2022 into consideration, nFCF grew at a 12-year CAGR of 6.0%, a really respectable progress fee certainly. The truth that ABC’s nFCF margin developments very a lot consistent with the corporate’s working margin means that the cashflows are steady and the corporate doesn’t endure from operational issues. In comparison with McKesson, AmerisourceBergen’s free cashflow margin is a tad weaker, which indicators that the corporate has potential room for margin enlargement.
Specializing in the effectivity of working capital administration, which is actually a key part in assessing a pharmaceutical distributor’s positioning, I monitor stock days (ID) and money conversion cycle (CCC), a mix metric that takes into consideration ID, days gross sales excellent (DSO) and days payables excellent (DPO). A overview of Determine 3 and Determine 4 clearly reveals that ABC displays the perfect working capital administration. All three corporations improved their money conversion cycle lately, and MCK is now performing nearly on par with ABC. Nonetheless, even a slight lead is efficacious on this sector as a result of characteristically low revenue margins. CAH continues to be the laggard and that is actually additionally evident from its underperformance when it comes to share worth. The very comparable IDs point out how essential it’s to take care of optimum relationships with each suppliers and clients. On this context, it additionally appears value mentioning that CAH seems to be in a relatively less-favorable bargaining place, as is indicated by its shorter payables interval of presently round 50 days, whereas ABC and MCK take 57 and 56 days to pay their suppliers, respectively.
AmerisourceBergen’s glorious working capital administration provides rise to a powerful money return on invested capital (CROIC), properly above the corporate’s weighted common price of capital (WACC). The metric takes nFCF as an alternative of internet working revenue after taxes into consideration. Determine 5 reveals ABC’s historic ROIC and CROIC compared to the corporate’s WACC, which has been calculated utilizing an fairness danger premium of 5%. AmerisourceBergen sometimes generates a return far larger than its WACC, thereby creating shareholder worth. Nevertheless, the comparatively steady efficiency shouldn’t be taken as a right, and potential operational inefficiencies will possible have a disproportionate impact on cashflows. Subsequently, you will need to monitor the corporate’s operations intently.
Stability Sheet High quality
As a non-cyclical, well-managed and highly-regulated enterprise, it doesn’t come as a shock that ABC’s stability sheet is kind of robust and the corporate’s long-term debt has been rated A- with a steady outlook by Fitch Scores. Over the past decade, AmerisourceBergen’s internet debt to nFCF has largely been under 1x nFCF. In 2021, the leverage ratio elevated to 2.4x nFCF, as a result of acquisition of a majority of Walgreens Boots Alliance’s (WBA) Alliance Healthcare companies.
ABC’s upcoming maturities seem regarding at first sight as a result of a lot of the firm’s debt is due within the subsequent couple of years. Nevertheless, the maturity ladder in Determine 6 needs to be seen in context with ABC’s cashflow and the general comparatively low quantity of debt. The corporate’s weighted common rate of interest is presently 2.67%, which may be very low certainly. That is primarily attributable to the corporate’s $1.5 billion of 0.737% notes that are due already subsequent yr. It, due to this fact, seems cheap to imagine that ABC’s curiosity burden will improve. Nevertheless, since its curiosity protection ratio (Determine 7) is fairly conservative for such a resilient enterprise, I’d not overemphasize ABC’s rate of interest danger within the present inflationary surroundings. Sometimes, the corporate spends solely round 7% of its pre-interest nFCF on curiosity bills.
Shareholder Returns And ABC’s Potential As A Dividend Progress Inventory
AmerisourceBergen started paying a dividend in 2001 and has elevated its payout to shareholders for 18 consecutive years. It presently pays a quarterly dividend of $0.46, which interprets to an annualized yield of 1.3% at a share worth of $140. ABC has been rising its dividend rather more aggressively previously (Determine 8) and it seems that the corporate will proceed to extend its distribution by $0.08 per yr, because it has achieved since 2017. This could theoretically translate to a rise by 4.3% in 2022, 3.7% in 2026 and three.0% in 2032. It seems cheap to count on not more than a 2.0% yield on price by 2032 – not a really compelling yield for a potential dividend progress inventory. The present yield of 1.4% can be under the corporate’s long-term common dividend yield of 1.6%, suggesting that the inventory is overvalued on this context. Buyers’ flight to worth because the starting of 2022 and the rising readability associated to the opioid litigations have helped the inventory admire in worth, from round $120 in December 2021.
In addition to the dividend, ABC additionally returns money to shareholders by way of share repurchases that greater than offset dilution as a result of stock-based compensations. Since 2010, the corporate, on common, retired 2.8% of its totally diluted shares excellent per yr, which interprets to an general enhance to earnings per share by nearly 38%. Critics would possibly argue that this may be seen as a type of monetary engineering and that the corporate is imitating earnings progress (on a per share foundation) by means of debt-funded share repurchases. Nevertheless, the corporate generated $17.8 billion in nFCF during the last twelve years and solely spent $10 billion on buybacks and $3 billion on dividends, leading to an extra nFCF of virtually $5 billion. Clearly, the corporate didn’t improve its leverage to fund buybacks, which is one other indicator of the corporate’s sound administration tradition. As proven above, the corporate additionally managed to develop its nFCF at a really wholesome long-term progress fee of 6% per yr.
Healthcare prices within the U.S. are excessive by any means and during the last a long time, they elevated a lot sooner than client worth inflation. On this context, the theoretical danger of a healthcare reform and the lately elevated fee of inflation needs to be saved in thoughts. A healthcare reform will possible restrict pharmaceutical corporations to extend their costs at or close to the speed of inflation (see my associated article), and as a intermediary’s enterprise that operates downstream, ABC is in a weaker place. Nevertheless, the corporate nonetheless possesses robust pricing energy as a result of its economies of scale and can probably proceed to have the ability to cross on worth will increase to its clients. Nonetheless, though ABC, MCK and CAH function in an oligopoly with excessive boundaries to entry, the commoditized connotation of the enterprise of sourcing and distributing prescription drugs needs to be saved in thoughts. That is additionally underlined by the truth that ABC’s margins are already very skinny and the corporate wants to make sure that it maintains its prime place when it comes to operational effectivity.
As already famous, ABC seems barely overvalued in comparison with its long-term common dividend yield of 1.6%. Different metrics, corresponding to price-to-earnings and price-to-sales (based mostly on present and ahead earnings) in addition to enterprise worth to nFCF and EBITDA (Determine 9) point out that the shares are roughly pretty valued. At a present P/E of round 17 and a ahead P/E of 13 (partly as a result of buybacks), ABC is certainly not what I’d name costly. Nevertheless, it shouldn’t be forgotten that the historic valuation, though it’s based mostly on information from 2010 to 2021, is a mirrored image of one of many strongest bull markets in fashionable historical past. Conversely, it may very well be argued that ABC’s inventory worth remained depressed for a big time frame as a result of uncertainties associated to the opioid litigations, and that time frame can be factored into the valuation.
Determine 10 and Determine 11 function long-term graphical comparisons of ABC’s inventory worth and enterprise worth (considering debt and lease obligations) to nFCF to facilitate understanding of the corporate’s present valuation relative to its money earnings.
I believe ABC is pretty valued at this level. In the long term, traders who open a place at this stage will most likely not do badly, however I personally desire to purchase at a reduction, corresponding to when the extent of the opioid trial was nonetheless unsure. Sadly, I didn’t have ABC on my radar again then. Nevertheless, I’m pleased to maintain the corporate on my watch record and patiently wait to have the ability to add this high-quality distribution enterprise to my portfolio upon any weaknesses, i.e., at a share worth of $120 or much less.
AmerisourceBergen is a high-quality and well-managed distributor of prescription drugs in america. It operates in an oligopoly with MCK and CAH, and though boundaries to entry are excessive, the enterprise remains to be solely that of an middleman with the razor-thin margins that include it. Nevertheless, in comparison with its rivals, ABC displays the perfect working capital administration, which is the inspiration for the corporate’s comparatively excessive returns on invested capital. Going ahead, it’s possible that ABC, like its friends, might face barely elevated challenges as a result of downstream location relative to pharmaceutical corporations and the possible persistence of the present inflationary surroundings. Nonetheless, its economies of scale and the related robust bargaining energy give these corporations an financial moat and I take into account ABC, because the best-in-class drug distributor, a welcome diversification in a portfolio.
Administration is shareholder-friendly, however the present comparatively low dividend yield, mixed with the single-digit dividend progress fee, makes the inventory relatively unattractive as a dividend progress candidate. Nonetheless, the corporate is a real sleep-at-night funding and is predicted to take care of its prime place and proceed to develop cashflow at a wholesome tempo. Subsequently, I see ABC as a complete return inventory relatively than a dividend progress inventory. The truth that ABC will not be actually uncovered to enterprise cycles additional provides to the conservative nature of this potential funding. Actually, a protracted bear market or an outright inventory market crash may even weigh on the ABC share worth, though most likely far lower than that of cyclical corporations.
Readability concerning the magnitude of the opioid lawsuits, in addition to the rising recognition of worth shares because the starting of 2022, have helped the languishing share worth fairly a bit and I take into account ABC pretty valued at $140. Subsequently, I’m pleased to maintain the corporate on my watch record and patiently wait to have the ability to add this high-quality distribution enterprise to my portfolio upon any weaknesses, i.e., at a share worth of $120 or much less.
Thanks very a lot for taking the time to learn my article. In case of any questions or feedback, I am very pleased to learn from you within the feedback part under.